

XX MPI: 2001-316444/33.  
DR N-PSDB; AAS07029.  
XX New polypeptides derived from Streptococcus agalactiae are useful to  
PT provide detection of, and vaccination against, Group B Streptococcus  
PT infections, particularly to prevent infection in neonates.  
XX  
XX Claim 1, Fig 1, 178pp, English.  
XX  
XX AAU03601-AAU03722 represent Group B Streptococcus (Streptococcus  
CC agalactiae) amino acid sequences of the invention. S. agalactiae is an  
CC encapsulated bacterium which is a major pathogen of humans causing sepsis  
CC and meningitis in neonates as well as adults. The S. agalactiae antigenic  
CC polypeptides are used to vaccinate against Group B Streptococcus  
CC infections, particularly to prevent infection in new born children  
CC arising from the maternal genital tract. An immunogenic composition is  
CC useful in the preparation of a medicament for the treatment of  
CC prophylaxis of Group B Streptococcus infection. The invention does not  
CC have the disadvantages of varied response rate associated with prior art  
CC capsid polysaccharide vaccination against Group B Streptococcus  
CC  
XX  
SQ Sequence 1055 AA;  
Query Match 74.4%; Score 3777.5; DB 4; Length 1055;  
Best Local Similarity 71.7%; Pred. No. 1,7e-221;  
Matches 756; Conservative 105; Mismatches 140; Indels 53; Gaps 5;  
QY 2 KKHLLKVALTLTAVSVTHNQEVSVKQPIKQTOASSISGADYAESGSKLKTINET 61  
DB 3 KKHLLKVALTLTAVSVTHNQEVSVKQPIKQTOASSISGADYAESGSKLKTINET 61  
QY 62 SGVVDVTVDLSPDKTTPBKIKONIAKAPREGELAVTENT-ESERKQITSGSLEQSK 120  
DB 63 NSTVDETVADLSPDKTTPBKIKONIAKAPREGELAVTENT-ESERKQITSGSLEQSK 121  
QY 121 SLSLKTAVSTGSMWELCDPTIKNTIVGSKGVKLSQTDHVLFSQADGQLQVNAS 180  
DB 122 DTASKKETLETSTWEMKDPVTRGDTLVGFSKSGINTLSQTHVLPSHADGQLQVNAS 181  
QY 181 PAFDPDKTALAEYTSRAGENGISQTDVQKKEINIEGEPFNSYLLKVTYIPYGHIGQ 240  
DB 182 PAFDPDKTALAEYTSRAGENGISQTDVQKKEINIEGEPFNSYLLKVTYIPYGHIGQ 241  
QY 241 DAFVDMKNIAEVLPESELTISDYAFAPAHAKQIDLPMLKAGELAFDPNQITGKLS 300  
DB 242 DAFVDMKNIAEVLPESELTISDYAFAPAHAKQIDLPMLKAGELAFDPNQITGKLS 301  
QY 301 ROLMRLAERAFKSNHITKTEFRGNSLKVYGEASFQNDLSQMLPGLKESBEATGNP 360  
DB 302 RHILIKLAEAFKSNHITKTEFRGNSLKVYGEASFQNDLSQMLPGLKESBEATGNP 361  
QY 361 GDDHYNNRVVLMTKSGKPSGLATENTYVNPDKSLMOBSEIDYTMLEDFYQKNSVT 420  
DB 362 GDBHTNNRVVLMTKSGKPSGLATENTYVNPDKSLMOBSEIDYTMLEDFYQKNSVT 421  
QY 421 GFSNKGLOKVKRNKLEIPKOHGVTITIGDPAFPAVDFQNTLAKYDLEEVKLPSTR 480  
DB 422 GFSNKGLOKVKRNKLEIPKOHGVTITIGDPAFPAVDFQNTLAKYDLEEVKLPSTR 481  
QY 481 KTGAPAFQSNNTKSPFASDLEETKEGAPNNRIETLELKDCLVTIGDAAFINHIYAI 540  
DB 482 KTGAPAFQSNNTKSPFASDLEETKEGAPNNRIETLELKDCLVTIGDAAFINHIYAI 541  
QY 541 LPESVGEIGSARQNGANLIPMGSKVTIGEMAFISRLLEHLDISEKOLTEIPVOAF 600  
DB 542 LPESVGEIGSARQNGANLIPMGSKVTIGEMAFISRLLEHLDISEKOLTEIPVOAF 601  
QY 601 SDNALKEVLLPALSITIREBAFRKNHKLQLEVASALSHIAFNALDDNDGDEQDNKVYK 660  
DB 602 SDNALKEVLLPALSITIREBAFRKNHKLQLEVASALSHIAFNALDDNDGDEQDNKVYK 661  
QY 661 THHNSYALMDGHRFIVDPDKLSTIVLEKILKLGIDYSTIRQTTQTQFRDMTTAGKA 720

DB 662 THHNSYALMDGHRFIVDPDKLSTIVLEKILKLGIDYSTIRQTTQTQFRDMTTAGKA 721  
QY 721 LLSKSNLROGEKQKLOEAOPLGVRVLDKALAKAEKALVTKATNGOLLERSINKAVL 760  
DB 722 LLSKSNLROGEKQKLOEAOPLGVRVLDKALAKAEKALVTKATNGOLLERSINKAVL 761  
QY 761 AYNNNAIKKAVNRLEKEIDLLTGVEGSPPLAQAATMVGSVTLKTPPLPBYTIGLVY 840  
DB 762 AYNNNAIKKAVNRLEKEIDLLTGVEGSPPLAQAATMVGSVTLKTPPLPBYTIGLVY 841  
QY 841 PFKSGGLIYALMSPDTIGGOKDAVGNPILANDENEGYHAALAVATLADYEGDIKTILN 900  
DB 842 PFKSGGLIYALMSPDTIGGOKDAVGNPILANDENEGYHAALAVATLADYEGDIKTILN 901  
QY 901 SKLSQTSIROVPTAAYHAGIFQALONAAABEQLLPRTGTHSEKSSSESSANSKDRGL 960  
DB 902 SLSDIKIKAIHQPLAKYHRLGIFQALIRNAAABEQLLPRTGTHSEKSSSESSANSKDRGL 957  
QY 961 QSNPK-----TN-----RGRHA 973  
DB 958 EKRLKPVDTKPIFNKALPNEKVDGPAKGNHINATNNSVAVTPDIRSEQLHKSSQSDV 1017  
QY 974 ILPRGSGKSPFYGLIGYTSVALLSITAIKKKK 1007  
DB 1018 NLPQTSKNNPIYELIGVSLCLFLVYAGKGG 1051  
RESULT 5  
ABP56257  
ID ABP56257 standard; protein; 1055 AA.  
XX  
AC ABP56257;  
XX  
DT 28-MAR-2003 (first entry)  
XX  
DE Serotype III group B Streptococcus strain COH1 BVH-A4 SEQ ID NO:2.  
XX  
KW Serotype III group B Streptococcus strain COH1; BVH-A4; streptococcus;  
KW antidiabetic; immunostimulant; vaccine; bacterial infection; sepsis;  
KW meningitis; pneumonia; cellulitis; osteomyelitis; septic arthritis;  
KW endocarditis; epiglottitis; osteomyelitis; amniocitis; endometritis;  
KW cellulitis; fasciitis; bacteraemia; urosepsis; peritonitis; emphysema;  
KW mastitis; streptococcal infection.  
XX  
OS Streptococcus sp.  
XX  
FH Key Location/Qualifiers  
FT Peptide 1..52 /label= signal  
FT Protein 23..105 /label= BVH-A4  
XX  
PN WO200286178-A2.  
XX  
PD 07-NOV-2002.  
XX  
PF 02-MAY-2002; 2002WO-CA000664.  
XX  
PR 02-MAY-2001; 2001US-0287712P.  
XX  
PA (SHIR-) SHIRE BIOCHEM INC.  
XX  
PI Martin D, Hamel J, Brodeur BR, Rioux S, Boyer M,  
XX MPI: 2003-120461/11.  
XX N-PSDB; ABZ21973.  
XX  
PT New BVH-A4 proteins and genes from serotype III Group B streptococcus,  
PT useful for treating or preventing streptococcal infection in infants,  
PT pregnant women, non-pregnant adults (e.g. pneumonia), or members of dairy  
PT herd (mastitis).  
XX

## ALIGNMENTS

	20,	17, Created)
UN-2001 (TrEMBLrel.	17, Last sequence update)	
UN-2001 (TrEMBLrel.	17, Last sequence update)	
UN-2001 (TrEMBLrel.	26, Last annotation update)	

TAXID=1314;

C: NBL1. Accu: 25.00  
L: AB006534; AAK33772.1; -  
GO:0009986; C:cell surface; IEA.

JUENCE 1008 AA; 111503 MM; 0.000000

Length 1008;

28 1008; CONBETVAC...  
...KOTASSISGADYAESSGSKLKINE 60

AKGPREQELKAVTENTSEKOITSGSOLBOSKE 120

. . . STVPSTNBEICDFTKNTLVGLSKGVBLSDTHLVLPSQADGIVLR

181 PAFPPDKCTAIABYTSRAGENGEISOLDVDGKRLNBGBVENCIMZ

241 DAFVINKIABVNLPELSBRLISDIAFALL

301 RQJMRLEBKF KOWALLA  
36

ATNTYVNPDKSLWQESPEIDYTKWLEEDFTYQKNSVT 420

RESULT 2  
Q8P1F7  
Q0D1F7  
PRELIMINARY;  
PRT; 1008 AA.

01-MAR-2004 (Tremblay, 26, last annotation)

Bacteria; Firmicutes; Laccobacillales

RP SEQUENCE FROM .....  
TC STRATN=MGAS8232;  
DOY-10 1073/pnas.062526099;

RA Parkins L.D.; Beres S.B.; Campbell D.C.; Musser J.M.; Yeary T.G.

RT outbreaks." Acad. Sci. U.S.A. 99:4668-4673 (2002).

DR InterPro; LRR Tp.  
DR InterPro; IPR007093; LRR Tp.  
DR InterPro; LRR Tp.